74.15 
0.86(1.15%) May 17, 4:00PM EDT
| Prev Close: | 75.01 |
|---|
| Open: | 73.53 |
|---|
| Bid: | 71.69 x 200 |
|---|
| Ask: | 74.84 x 200 |
|---|
| 1y Target Est: | 73.94 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 73.50 - 74.16 |
|---|
| 52wk Range: | 51.20 - 75.67 |
|---|
| Volume: | 1,092,063 |
|---|
| Avg Vol (3m): | 1,584,290 |
|---|
| Market Cap: | 182.20B |
|---|
| P/E (ttm): | 18.82 |
|---|
| EPS (ttm): | 3.94 |
|---|
| Div & Yield: | 2.53 (3.40%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Novartis AG (NVS): Today's Featured Drugs Laggardat TheStreet(Fri, May 17)
- 3 Companies That Put the "Tech" in "Biotech"at Motley Fool(Thu, May 16)
- Novartis says no intention of pursuing Actavis, Bloomberg reportstheflyonthewall.com(Thu, May 16)
- Early Movers: WMT, KSS, CSCO & Moreat CNBC(Thu, May 16)
- Morning Briefing: 10 Things You Should Knowat TheStreet(Thu, May 16)
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Good News for Novartis' IlarisZacks(Wed, May 15)
- Why Bristol-Myers Is Soaringat Motley Fool(Wed, May 15)
- A Wall Street Transcript Interview with Russell Sims, Portfolio Manager and Director of Research for Osborn Rohs Williams & Donohoe: Three Equity Strategies for Investing in Quality CompaniesWall Street Transcript(Wed, May 15)
- Europe Shares Close Higher as Risk-On Rally Resumesat CNBC(Wed, May 15)
- Novartis Reaches New 52-Week High (NVS)at TheStreet(Wed, May 15)
- Aveo Screwed Up but Its Kidney Cancer Drug Is Realat TheStreet(Wed, May 15)
- The Hidden Opportunity of the Novel Coronavirusat Motley Fool(Wed, May 15)
- Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stockat Seeking Alpha(Wed, May 15)
- Big Pharma's Biggest Winnersat Motley Fool(Mon, May 13)
Key Statistics
| Forward P/E (1 yr): | 13.71 |
|---|
| P/S (ttm): | 3.19 |
|---|
| Ex-Dividend Date: | 26-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.29 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 2.77 |
|---|
Business Summary
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary...
View More